k-tab- potassium chloride tablet, film coated, extended release
abbvie inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - k-tab is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of k-tab during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of human milk is about 13 meq per liter. since potassium from oral supplements such as k-
humira 40mg0.8ml solution for injection vials
abbvie ltd - adalimumab - solution for injection - 50mg/1ml
kaletra 200mg50mg tablets
abbvie ltd - ritonavir; lopinavir - tablet - 50mg ; 200mg
kaletra 100mg25mg tablets
abbvie ltd - ritonavir; lopinavir - tablet - 25mg ; 100mg
norvir 100mg tablets
abbvie ltd - ritonavir - tablet - 100mg
viekirax 12.5mg75mg50mg tablets
abbvie ltd - ombitasvir; ritonavir; paritaprevir - tablet - 12.5mg ; 50mg ; 75mg
exviera 250mg tablets
abbvie ltd - dasabuvir sodium monohydrate - tablet - 250mg
humira 40mg0.4ml solution for injection pre-filled pen
abbvie ltd - adalimumab - solution for injection - 100mg/1ml
humira 40mg0.4ml solution for injection pre-filled syringes
abbvie ltd - adalimumab - solution for injection - 100mg/1ml
norvir 100mg oral powder sachets
abbvie ltd - ritonavir - powder - 100mg